# Diabetes Research Hub — Monitor Report
**Run date:** 2026-07-06 (automated)
**Previous monitor run:** 2026-07-05
**Data current as of:** clinical trials 2026-07-06, PubMed 2026-07-06, gap analysis 2026-07-05

---

## Bottom line

Quiet cycle. Zero net change in the trial universe since yesterday (0 new, 0 removed, 0 status changes, 0 new results in the 07-05→07-06 diff). PubMed rotated 5 papers in / 5 out. No new breaking news beyond what the corpus already reflects. **Nothing requires urgent action.** The one item worth a human glance: the teplizumab expanded-indication approval (June 12) is now propagating through both the trial set and PubMed — worth a tracker note if not already logged.

---

## File System Status

All primary script outputs are fresh:

| File | Last modified | Status |
|------|---------------|--------|
| clinical_trials_latest.json | 2026-07-06 | Current (839 trials) |
| pubmed_recent_latest.json | 2026-07-06 | Current (155 papers) |
| hub_monitor_report.md | 2026-07-06 | Current |
| literature_gap_data.json | 2026-07-05 | 1 day old |
| literature_gap_report.md | 2026-07-05 | 1 day old |

hub_monitor.py flagged **787 result files older than 14 days** — these are overwhelmingly dated daily snapshot archives (clinical_trials_snapshot_*, pubmed_recent_snapshot_*) and are expected to be stale by design. No action needed. Total files tracked: 1015 (4 new, 31 modified, 0 removed vs. prior scan).

---

## Clinical Trial Changes

**Since last snapshot (07-05 → 07-06): no changes.** New trials: 0. Status changes: 0. New results posted: 0.

**Phase 3 RECRUITING trials of interest (42 total; key programs):**

- **Vertex — VX-880 / zimislecel** (NCT04786262, and NCT06832410 in T1D + kidney transplant) — both PHASE3 RECRUITING. The flagship stem-cell-derived islet cure program. Still no FDA approval logged (web check confirms none as of today).
- **Eli Lilly — Baricitinib** BARICADE-PRESERVE (NCT07222332, newly-diagnosed T1D) and delay-of-stage-3 (NCT07222137) — both PHASE3 RECRUITING. Baricitinib appears in PubMed (3 hits) — an immunomodulation-to-preserve-beta-cell thesis worth tracking as a Tier-1 combination-mapping candidate.
- **Sanofi — Teplizumab** (NCT07088068, ages 1–25, stage 3 T1D) — PHASE3 RECRUITING. See Breaking News; expanded pediatric indication now approved.
- **Novo Nordisk — Insulin icodec** in T1D (NCT07076199) — PHASE3 RECRUITING.
- **vTv — Cadisegliatin** (glucokinase activator, NCT06334133) — PHASE3 RECRUITING. Note: glucokinase is one of the lowest-volume domains (852 pubs) yet has an active Phase 3; relevant to several top gap intersections below.

**Recently posted results (last 7 days), evidence level = trial registry (verify against publication before citing):**

- **NCT06010004 — Orforglipron long-term safety in T2D (Lilly, PHASE3)** — results posted 2026-06-30. Ties to the Foundayo oral GLP-1 approval; a T2D indication read-through candidate.
- **NCT06340854 — Insulin icodec switch study in T2D (Novo, PHASE3)** — results posted 2026-07-02.
- Three NA/behavioral trials (Johns Hopkins remote DFU monitoring, pregnancy weight-gain RCT, SUNY Buffalo family-based T1D treatment) — lower priority.

---

## PubMed Highlights

155 unique papers across 16 domains (30-day lookback). Rotation since yesterday: **5 in / 5 out.**

**Cross-domain papers (highest value — appear in ≥2 alert domains):**

- *PMID 42398072* — "A historical journey of metabolite-protein interaction discovery: from data harmonization to AI-driven prediction" — **3 domains.** Directly relevant to Tier-1 Multi-Omics Biomarker Integration.
- *PMID 42394981* — "Efficacy and safety of incretin-based therapies in T2D: a network meta-analysis" — **3 domains.**
- *PMID 42387220* — "Overcoming Immunological Barriers in MSC-Derived Insulin-Producing Cells through CRISPR-Based Hypoimmunogenic Engineering" — 2 domains; relevant to T1D cell-cure program.
- *PMID 42332392 / 42295172* — two teplizumab (Tzield) delay/expanded-indication papers — 2 domains each; corroborates the approval news below.

**Key-therapy tracking (30-day mention counts):** orforglipron 11, retatrutide 6, teplizumab 6, CagriSema 5, dapagliflozin 50, icodec 4, baricitinib 3, **zimislecel 0**. Zimislecel's zero-count despite an active Phase 3 is a persistent signal that the Vertex program publishes under "VX-880" — a terminology gap the alert queries may be missing.

**New today (5):** pancreas transplant in T2D survey (PMID 42256091), diabetic PAD biomarkers (42402062), revisional bariatric surgery (42402507), single-cell-guided hydrogel EV wound therapy (42402577), probiotic/prebiotic + colorectal cancer NHANES (42402613). Routine — none breaking.

---

## Gap Analysis Summary

Top 5 under-researched intersections (Gap Score 100, BRONZE validation — single analytical source, expert confirmation required):

| Rank | Intersection | Joint Pubs | Tier-1 alignment |
|------|--------------|-----------|------------------|
| 1 | Beta Cell Regen × Health Equity | 0 | ✔ Epidemiology / Health Equity (#6) |
| 2 | Insulin Resistance × Islet Transplant | 1 | — |
| 3 | Islet Transplant × Drug Repurposing | 0 | ✔ Drug Repurposing (#4) |
| 4 | Islet Transplant × Health Equity | 0 | ✔ Health Equity (#6) |
| 5 | Gene Therapy × LADA | 0 | — |

**Tier-1 mapping:** The gap list is dominated by **Drug Repurposing** and **Health Equity** intersections — both Tier-1 contribution areas. Ranks 3 (Islet Transplant × Drug Repurposing) and 8/12/13 (Glucokinase, Drug Repurposing × Health Equity/LADA) are the most actionable computational targets: they sit inside our declared strengths and have literal zero co-publication. Recommend prioritizing a repurposing-screen synthesis on islet protection as the next Project-1 candidate. Caveat per Doctrine: gap scores are relative bibliometric signals, not confirmed white space — verify each with a combined-term PubMed/Cochrane search before committing.

---

## Breaking News (web check, last ~30 days)

- **[Significant] Teplizumab (Tzield) accelerated FDA approval — June 12, 2026**, expanding to children/adolescents 8–17 recently diagnosed with stage 3 T1D; first disease-modifying therapy for that population. Corroborated by two PubMed entries in today's corpus and the active Sanofi Phase 3 (NCT07088068). *Action: confirm this is logged in the tracker.*
- **[Significant] Retatrutide TRANSCEND-T2D-1 Phase 3 results (ADA Scientific Sessions, June 2026)** — up to ~2.0% HbA1c reduction, ~16.8% weight loss at 40 weeks in T2D. Multiple retatrutide Phase 3 arms (TRANSCEND-T2D-2/-3) are ACTIVE_NOT_RECRUITING in our tracker.
- **[Context, not new] Orforglipron (Foundayo)** — FDA approved April 1, 2026 for chronic weight management; T2D long-term safety results just posted (NCT06010004). Oral GLP-1 with no food/water restriction.
- No FDA approval for zimislecel/VX-880 as of this run.

Evidence note: news items above are secondary-source (press/conference) — GOLD/SILVER confirmation requires the primary publications or FDA labels before any of these enter the hub as claims.

---

## Recommended Actions

1. **Tracker:** Confirm the teplizumab pediatric expanded-indication (FDA, 2026-06-12) and the two newly-posted Phase 3 results (orforglipron NCT06010004, icodec NCT06340854) are recorded in Diabetes_Research_Tracker.xlsx.
2. **Terminology fix:** Add "VX-880" as an alias to the zimislecel alert query in baseline_pubmed_alerts.py — current zero-count is almost certainly a keyword miss, not genuine absence.
3. **Next computational project:** Advance the **Islet Transplant × Drug Repurposing** gap (rank 3, Tier-1 aligned) — run a network-pharmacology screen of approved immunosuppressants/other agents against islet-protection targets. Verify the gap with a combined-term PubMed + Cochrane/PROSPERO search first.
4. **Refresh cadence:** Gap analysis is 1 day old — fine. No re-run needed. If desired weekly, next run ~2026-07-12: `python project1_literature_gap_analysis.py`.
5. No stale primary data. All scripts (baseline_clinical_trials.py, baseline_pubmed_alerts.py, hub_monitor.py) ran on schedule.

---
*Automated review run. No source files were modified. Gap classifications are BRONZE (Research Doctrine v1.0); news items are secondary-source pending primary confirmation.*
